1391633-70-7

Basic information

• Product Name: N-(4-flurophenyl)-N-(11β,15β-dihydroxykaur-16-ene-4α-yl)urea
• Synonyms: N-(4-flurophenyl)-N-(11β,15β-dihydroxykaur-16-ene-4α-yl)urea
• CAS NO: 1391633-70-7
• Molecular Weight: 442.574
• Mol File: 1391633-70-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4-flurophenyl)-N-(11β,15β-dihydroxykaur-16-ene-4α-yl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-flurophenyl)-N-(11β,15β-dihydroxykaur-16-ene-4α-yl)urea(1391633-70-7)
• EPA Substance Registry System: N-(4-flurophenyl)-N-(11β,15β-dihydroxykaur-16-ene-4α-yl)urea(1391633-70-7)

Safety Data

• Hazardous Substances Data: 1391633-70-7(Hazardous Substances Data)

Upstream product

• 57719-76-3 ent-11α,15α-Dihydroxykaur-16-en-19-oic acid 
• 1391633-67-2 4α-isocyanato-11β,15β-dihydroxykaur-16-ene 
• 371-40-4 4-fluoroaniline 

Relevant articles and documents

Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: Potential impact in diabetes

The biological screening of a collection of nature occurring diterpenoids against 11β-HSD1 resulted in the discovery of the lead compound 1b, which pointed to the therapeutic potential for type 2 diabetes. Subsequently, an optimization project was initiated. Starting from compound 1b and its counterpart 2, the hemi-synthesis was performed on kaurenic acid scaffolds yielding 36 derivatives. Further evaluations on both human and mouse 11β-HSD revealed that seven urea derivatives exhibited significant improved potency and selectivity. Especially, the urea 19a has an IC50 (human 11β-HSD1) = 9.4 nM and selectivity index (human 11β-HSD) > 10,649. The 2D and 3D binding models of the complex 19a/11β-HSD1 were generated using docking simulations. Based on the results, the structural-activity relationships (SARs) of compounds 1b and 2 were also discussed.